Multiple Ascending Dose Study of LY4256984 in Participants with Sporadic Amyotrophic Lateral Sclerosis

2025-521295-60-00 Protocol J6I-MC-OWAA Human pharmacology (Phase I) - First administration to humans Ongoing, recruiting

Start 29 Jan 2026 · Status Ongoing, recruiting · 4 EU/EEA countries · 7 sites · Protocol J6I-MC-OWAA

Overview

Sponsor-declared trial summary

Phase Human pharmacology (Phase I) - First administration to humans
Status Ongoing, recruiting
Participants planned 42
Countries 4
Sites 7

Sporadic Amyotrophic Lateral Sclerosis

Key facts

Sponsor
Eli Lilly & Co.
Participant type
Patients
Age range
18-64 years, 65+ years
Gender
Male and Female
Therapeutic area
Diseases [C] - Nervous System Diseases [C10]
Trial duration
29 Jan 2026 → ongoing
Decision date (initial)
2025-09-04
Transition trial
No
Low-intervention
No
Rare-disease indication
Yes
Vulnerable population
Yes

External identifiers

EU CT number
2025-521295-60-00
WHO UTN
U1111-1321-6118

Trial design

CTIS Part I — objectives, methods, condition coding

Conditions and MedDRA coding

Sporadic Amyotrophic Lateral Sclerosis

VersionLevelCodeTermSystem organ class
27.1 PT 10002026 Amyotrophic lateral sclerosis 100000004852

Sponsors and contacts

Sponsor organisations, regulatory contacts, third parties

Eli Lilly & Co.

Sponsor organisation
Eli Lilly & Co.
Address
1 Lilly Corporate Center
City
Indianapolis
Postcode
46285-0001
Country
United States

Scientific contact point

Organisation
Eli Lilly & Co.
Contact name
Lilly Clinical Trials information desk

Public contact point

Organisation
Eli Lilly & Co.
Contact name
Lilly Clinical Trials information desk

Locations

4 EU/EEA countries · 7 investigational sites

By country

CountryMS statusPlanned subjectsSites
Belgium Ongoing, recruiting 5 1
Germany Ongoing, recruiting 10 3
Netherlands Ongoing, recruiting 5 1
Spain Ongoing, recruiting 10 2
Rest of world
Canada
12

Investigational sites

Belgium

1 site · Ongoing, recruiting
UZ Leuven
Neurology, Herestraat 49, 3000, Leuven

Germany

3 sites · Ongoing, recruiting
Rostock University Medical Center
Klinik und Poliklinik für Neurologie /Sektion für Translationale Neurodegeneration Albrecht Kossel, Gehlsheimer Strasse 20, Gehlsdorf, Rostock
Universitaetsklinikum Ulm AöR
Studienzentrum Neurologie, Oberer Eselsberg 45, Eselsberg, Ulm
Universitaetsklinikum Schleswig-Holstein AöR
Campus Luebeck / Präzisionsneurologie Haus D1, Ratzeburger Allee 160, 23538, Luebeck

Netherlands

1 site · Ongoing, recruiting
Universitair Medisch Centrum Utrecht
Neurology, Heidelberglaan 100, 3584 CX, Utrecht

Spain

2 sites · Ongoing, recruiting
Hospital Universitario Y Politecnico La Fe
Neurologist, Avenida Fernando Abril Martorell 106, 46026, Valencia
Bellvitge University Hospital
Neurologist, Carrer De La Feixa Llarga S/N, 08907, L'Hospitalet De Llobregat

Country notifications

Trial-start, recruitment-start, end and early-termination notifications submitted per Member State

Country Trial startTrial end Recruitment startRecruitment end Early termination
Belgium 2026-02-06 2026-02-12
Germany 2026-02-10 2026-02-19
Netherlands 2026-01-29 2026-02-03
Spain 2026-01-30 2026-02-16

Application history

3 submissions — initial application plus substantial / non-substantial modifications

#TypeCodeSubmittedReference MSConclusionDecision date
1 INITIAL IN 2025-05-22 Germany Acceptable with conditions
2025-09-02
2025-09-02
2 NON SUBSTANTIAL MODIFICATION NSM-1 2025-09-09 Acceptable with conditions
2025-09-02
2025-09-09
3 SUBSTANTIAL MODIFICATION SM-1 2025-10-07 Germany Acceptable
2025-11-27
2025-11-28